Carcinoma, Non-Small-Cell Lung Clinical Trials in Houston, Texas

21 studies are recruiting for carcinoma, non-small-cell lung in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

   The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Cancer Center ( Site 0191), Houston, Texas

   Locations

   242 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06623422 on ClinicalTrials.gov

2. Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

   The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nano…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Millennium Oncology, Houston, Texas

   Locations

   10 in total

   Run by

   Genprex, Inc.

   See if you can join NCT04486833 on ClinicalTrials.gov

3. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

   This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   16 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07154290 on ClinicalTrials.gov

4. Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

   This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery o…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Southwest Oncology Associates, Houston, Texas

   Locations

   87 in total

   Run by

   Pfizer

   See if you can join NCT07227298 on ClinicalTrials.gov

5. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   418 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06119581 on ClinicalTrials.gov

6. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

   The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   369 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06890598 on ClinicalTrials.gov

7. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

   The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   24 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06400472 on ClinicalTrials.gov

8. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

9. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

   The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   203 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06667076 on ClinicalTrials.gov

10. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is comp…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    43 in total

    Run by

    Johnson & Johnson Enterprise Innovation Inc.

    See if you can join NCT06667908 on ClinicalTrials.gov

11. A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

    The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic n…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Oncology Consultants Cancer Center, Houston, Texas

    Locations

    13 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07227025 on ClinicalTrials.gov

12. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas

    Locations

    46 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT04165070 on ClinicalTrials.gov

13. KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

    This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substu…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas

    Locations

    47 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT04165798 on ClinicalTrials.gov

14. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Texas Oncology - Gulf Coast, Houston, Texas

    Locations

    440 in total

    Run by

    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

15. Intratumoral N17350 in Advanced Solid Tumors

    The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop grow…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    Onchilles Pharma Inc

    See if you can join NCT07339176 on ClinicalTrials.gov

16. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston, Texas

    Locations

    62 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT05208762 on ClinicalTrials.gov

17. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    48 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT06131840 on ClinicalTrials.gov

18. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston, Texas

    Locations

    372 in total

    Run by

    Pfizer

    See if you can join NCT06758401 on ClinicalTrials.gov

19. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Oncology Consultants, PA, Houston, Texas

    Locations

    158 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

20. A Study of LY4175408 in Participants With Advanced Cancer

    The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    27 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07046923 on ClinicalTrials.gov

21. Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

    This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative surgery will be eligible for participation in the study. The study wil…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Houston Methodist Neal Cancer Center, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT06566443 on ClinicalTrials.gov